PIPELINE

We’re on a mission to revolutionize antimicrobial eye care.
And we’re just getting started.

AV2019F2 for bacterial keratitis is our lead drug candidate and indication, but we have so much more in store. We believe AV2019F2 is more than a single indication candidate, it will be a platform for treating many critical ophthalmic infections such as conjunctivitis, endophthalmitis, surgical prophylactic treatments, and many others.

Want to learn more about our latest and greatest science?